Lifecore Biomedical price to free cash flow LFCR

Market value divided by free cash flow over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 126×; Mar 2018
Peer median: 11.4×

Lifecore Biomedical's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Mar 2018, at 126×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2018	126×	124×	139×
2017	50.0×	23.7×	54.1×
2016	n/m a value too high to mean anything
2015	92.0×	38.6×	101×
2014	65.7×	27.3×	65.7×
2013	34.3×	14.4×	34.9×
2012	13.9×	13.2×	17.5×

Against its peers

Companies in Drug Manufacturers - General nearest Lifecore Biomedical's size, closest first, today.

Company	Price to free cash flow
LFCRLifecore Biomedical	n/m
NATRNatures Sunshine Products	11.8×
ARVNArvinas	n/m
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
LFVNLifevantage	11.0×
ABUSArbutus Biopharma	n/m
SPROSpero Therapeutics	n/m
Peer median	11.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Lifecore Biomedical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.